Table of Contents 
ISRN Gastroenterology
Volume 2011 (2011), Article ID 645641, 8 pages
http://dx.doi.org/10.5402/2011/645641
Research Article

Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System

Rancés Blanco,1 Enrique Rengifo,1 Mercedes Cedeño,1 Charles E. Rengifo,2 Daniel F. Alonso,3 and Adriana Carr4

1Department of Quality Control, Center of Molecular Immunology, Havana 11600, Cuba
2Department of Pathology, Manuel Fajardo General Hospital, Havana 10400, Cuba
3Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Bernal B1876BXD, Argentina
4Research and Development Direction, Center of Molecular Immunology, 216 Street and 15 Avenue Atabey, Playa. P.O. Box 16040, Havana 11600, Cuba

Received 21 September 2010; Accepted 3 November 2010

Academic Editors: D. Coppola and M. de Bernard

Copyright © 2011 Rancés Blanco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” Ca-A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. Cotran, V. Kumar, and T. Collins, “The gastrointestinal tract,” in Robbins Pathologic Basis of Disease, pp. 718–721, WB Saunders, Philadelphia, Pa, USA, 6th edition, 1999. View at Google Scholar
  3. M. J. Bowles and I. S. Benjamin, “ABC of the upper gasrointestinal tract: cancer of the stomach and pancreas,” British Medical Journal, vol. 323, no. 7326, pp. 1413–1416, 2001. View at Google Scholar · View at Scopus
  4. L. B. Saltz, N. J. Meropol, P. J. Loehrer, M. N. Needle, J. Kopit, and R. J. Mayer, “Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1201–1208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Layke and P. P. Lopez, “Esophageal cancer: a review and update,” American Family Physician, vol. 73, no. 12, pp. 2187–2194, 2006. View at Google Scholar · View at Scopus
  6. S. Zhang, C. Cordon-Cardo, H. S. Zhang et al., “Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides,” International Journal of Cancer, vol. 73, no. 1, pp. 42–49, 1997. View at Publisher · View at Google Scholar
  7. A. Irie, S. Koyamat, Y. Kozutsumi, T. Kawasaki, and A. Suzuki, “The molecular basis for the absence of N-glycolylneuraminic acid in humans,” Journal of Biological Chemistry, vol. 273, no. 25, pp. 15866–15871, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Vazquez, M. Alfonso, B. Lanne et al., “Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids,” Hybridoma, vol. 14, no. 6, pp. 551–556, 1995. View at Google Scholar · View at Scopus
  9. G. Marquina, H. Waki, L. E. Fernandez et al., “Gangliosides expressed in human breast cancer,” Cancer Research, vol. 56, no. 22, pp. 5165–5171, 1996. View at Google Scholar · View at Scopus
  10. A. Carr, A. Mullet, Z. Mazorra et al., “A mouse IgG monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors,” Hybridoma, vol. 19, no. 3, pp. 241–247, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. J. P. Oliva, Z. Valdés, A. Casacó et al., “Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc,” Breast Cancer Research and Treatment, vol. 96, no. 2, pp. 115–121, 2006. View at Publisher · View at Google Scholar
  12. S. Hakomori, “Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens,” Advances in Cancer Research, vol. 52, pp. 257–331, 1989. View at Google Scholar · View at Scopus
  13. R. F. Irie and M. H. Ravindranath, “Gangliosides as target for monoclonal antibodies therapy of cancer,” in Therapeutic Monoclonal Antibodies, C. A. K. Borrebaeck and G. W. Larrick, Eds., pp. 75–94, Stockton Press, New York, NY, USA, 1990. View at Google Scholar
  14. P. O. Livingston, S. Zhang, and K. O. Lloyd, “Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale,” Cancer Immunology Immunotherapy, vol. 45, no. 1, pp. 1–9, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Fredman, O. Nilsson, and L. Svennerholm, “Colorectal carcinomas have a characteristic ganglioside pattern,” Medical Biology, vol. 61, no. 1, pp. 45–48, 1983. View at Google Scholar
  16. E. V. Diatlovitskaia, E. A. Tekieva, A. F. Lemenovskaia, O. G. Somova, and L. D. Bergel'son, “Gangliosides GM3 and GD3 in human stomach and breast tumors,” Biokhimiya, vol. 56, no. 3, pp. 560–564, 1991. View at Google Scholar · View at Scopus
  17. E. A. Tekieva and E. V. Diatlovitskaia, “Ganglioside lactones in human stomach and breast tumors,” Biokhimiya, vol. 58, no. 10, pp. 1641–1644, 1993. View at Google Scholar · View at Scopus
  18. T. Kawai, A. Kato, H. Higashi, S. Kato, and M. Naiki, “Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry,” Cancer Research, vol. 51, no. 4, pp. 1242–1246, 1991. View at Google Scholar · View at Scopus
  19. P. Tangvoranuntakul, P. Gagneux, S. Diaz et al., “Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12045–12050, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Bardor, D. H. Nguyen, S. Diaz, and A. Varki, “Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells,” Journal of Biological Chemistry, vol. 280, no. 6, pp. 4228–4237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. N. Malykh, R. Schauer, and L. Shaw, “N-Glycolylneuraminic acid in human tumours,” Biochimie, vol. 83, no. 7, pp. 623–634, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Higashi, M. Naiki, S. Matuo, and K. Okouchi, “Antigen of 'serum sickness' type of heterophile antibodies in human sera: identification as gangliosides with N-glycolylneuraminic acid,” Biochemical and Biophysical Research Communications, vol. 79, no. 2, pp. 388–395, 1977. View at Google Scholar · View at Scopus
  23. T. Koda, T. Shimosakoda, S. Nishinaka et al., “Diagnosis of hepatocellular carcinoma using chicken anti-monoclonal antibody—as tumor marker on the heterophilic hanganutziu-deicher antigen,” Gan To Kagaku Ryoho, vol. 21, pp. 2771–2777, 1994. View at Google Scholar
  24. T. Nishimaki, K. Kano, and F. Milgrom, “Hanganutziu-Deicher antigen and antibody in pathologic sera and tissues,” Journal of Immunology, vol. 122, no. 6, pp. 2314–2318, 1979. View at Google Scholar · View at Scopus
  25. C. M. Gordon and K. O. Lloyd, “Endocytosis and recycling of gangliosides in a human melanoma cell line: inhibitory effect of brefeldin A and monensin,” Archives of Biochemistry and Biophysics, vol. 315, no. 2, pp. 339–344, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. B. K. Gillard, R. G. Clement, and D. M. Marcus, “Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways,” Glycobiology, vol. 8, no. 9, pp. 885–890, 1998. View at Google Scholar · View at Scopus
  27. U. Distler, J. Souady, M. Hülsewig et al., “Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer,” Molecular Cancer Therapeutics, vol. 7, no. 8, pp. 2464–2475, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Hirabayashi, H. Kasakura, and M. Matsumoto, “Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers,” Japanese Journal of Cancer Research, vol. 78, no. 3, pp. 251–260, 1987. View at Google Scholar
  29. S. Watarai, Y. Kushi, R. Shigeto et al., “Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides,” Journal of Biochemistry, vol. 117, no. 5, pp. 1062–1069, 1995. View at Google Scholar · View at Scopus
  30. W. Blonski and K. R. Reddy, “Hepatitis C virus infection and hepatocellular carcinoma,” Clinics in Liver Disease, vol. 12, no. 3, pp. 661–674, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Koda, M. Aosasa, H. Asaoka, H. Nakaba, and H. Matsuda, “Application of tyramide signal amplification for detection of N-glycolylneuraminic acid in human hepatocellular carcinoma,” International Journal of Clinical Oncology, vol. 8, no. 5, pp. 317–321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Osorio, E. Gracia, E. Rodríguez et al., “Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study,” Cancer Biology and Therapy, vol. 7, no. 4, pp. 488–495, 2008. View at Google Scholar · View at Scopus
  33. A. Carr, C. Mesa, M. D. C. Arango, A. M. Vázquez, and L. E. Fernández, “In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody,” Hybridoma and Hybridomics, vol. 21, no. 6, pp. 463–468, 2002. View at Google Scholar · View at Scopus
  34. L. Roque-Navarro, K. Chakrabandhu, J. de León et al., “Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 2033–2041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. De Leòn, A. Fernández, C. Mesa, M. Clavel, and L. E. Fernández, “Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells,” Cancer Immunology, Immunotherapy, vol. 55, no. 4, pp. 443–450, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. de León, A. Fernández, M. Clavell et al., “Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25− effector and naturally occurring CD4+CD25+ regulatory T cells function,” International Immunology, vol. 20, no. 4, pp. 591–600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Labrada, M. Clavell, Y. Bebelagua et al., “Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy,” Expert Opinion on Biological Therapy, vol. 10, no. 2, pp. 153–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Eaton, “World cancer rates set to double by 2020,” British Medical Journal, vol. 326, no. 7392, p. 728, 2003. View at Google Scholar · View at Scopus
  39. A. Carr, E. Rodríguez, M. D. C. Arango et al., “Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine,” Journal of Clinical Oncology, vol. 21, no. 6, pp. 1015–1021, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Alfonso, A. Díaz, A. M. Hernández et al., “An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients,” Journal of Immunology, vol. 168, no. 5, pp. 2523–2529, 2002. View at Google Scholar · View at Scopus